Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

Ventyx Biosciences, a clinical-stage biopharmaceutical company, has announced key presentations at upcoming investor conferences. Executives will discuss the company’s focus on developing innovative oral therapies for inflammatory diseases. The conferences include the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, the Stifel 2022 Healthcare Conference on November 15, 2022, and the Jefferies London Healthcare Conference on November 17, 2022. Webcasts of the presentations will be available on Ventyx's website for thirty days following each event.

ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that Company executives will provide a company overview during fireside chats at the following upcoming investor conferences:

• Event: Credit Suisse 31st Annual Healthcare Conference
  Location: Rancho Palos Verdes, CA
  Date: Wednesday, November 9, 2022
  Time: 12:50-1:20 PM PT / 3:50-4:20 PM ET

• Event: Stifel 2022 Healthcare Conference
  Location: New York, NY
  Date: Tuesday, November 15, 2022
  Time: 3:00-3:30 PM ET

• Event: Jefferies London Healthcare Conference
  Location: London, United Kingdom
  Date: Thursday, November 17, 2022
  Time: 8:35-9:05 AM GMT / 3:35-4:05 AM ET

Members of the Ventyx management team will also host investor meetings during the conferences.

Webcasts of the presentations will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of each event for thirty days.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three clinical-stage internally discovered programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California.

Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com

FAQ

What is Ventyx Biosciences focusing on at the upcoming investor conferences?

Ventyx Biosciences focuses on presenting its innovative oral therapies aimed at treating inflammatory diseases.

When is the Credit Suisse 31st Annual Healthcare Conference?

The Credit Suisse 31st Annual Healthcare Conference is on November 9, 2022.

Where will the Stifel 2022 Healthcare Conference take place?

The Stifel 2022 Healthcare Conference will be held in New York, NY.

What are the dates for the Jefferies London Healthcare Conference?

The Jefferies London Healthcare Conference is scheduled for November 17, 2022.

How can investors access Ventyx's conference presentations?

Investors can access the presentations through webcasts available on Ventyx's website.

What type of therapies is Ventyx developing?

Ventyx is developing novel oral therapies for autoimmune and inflammatory disorders.

What are the timestamps for Ventyx's presentations at the conferences?

Ventyx's presentations are scheduled for 12:50-1:20 PM PT on Nov 9, 3:00-3:30 PM ET on Nov 15, and 8:35-9:05 AM GMT on Nov 17.